PillRx only · Injection · Intramuscular
Paliperidone Palmitate
Brands: Erzofri Extended-Release · Invega Sustenna · Paliperidone Palmitate
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US11 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 5 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$2341.003
Latest avg · Jul 22, 2026
+2%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
293K
Rx · 2026 Q1
372K
Units dispensed
-8%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Shandong Luye Pharmaceutical Co., Ltd. | unknown | 7 | SUPPLYING |
| Janssen Pharmaceuticals, Inc. | unknown | 7 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.